Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IN8BIO, Inc. INAB

Healthcare Biotechnology
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400,... see more

Recent & Breaking News (NDAQ:INAB)

IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock

GlobeNewswire August 11, 2022

IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients

GlobeNewswire July 27, 2022

Newly Issued European Patent Broadens IN8bio's Drug Resistant Immunotherapy (DRI) Platform

GlobeNewswire July 21, 2022

IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development

GlobeNewswire July 12, 2022

IN8bio to Present at July Investor and Scientific Conferences

GlobeNewswire June 30, 2022

IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences

GlobeNewswire June 8, 2022

IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022

GlobeNewswire June 6, 2022

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell "Off-the-Shelf" Induced Pluripotent Stem Cell Platform

GlobeNewswire May 17, 2022

IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2022

IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting

GlobeNewswire May 5, 2022

IN8bio to Present at May Investor and Scientific Conferences

GlobeNewswire May 4, 2022

IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments

GlobeNewswire April 13, 2022

IN8bio to Present at April Investor and Scientific Conferences

GlobeNewswire April 5, 2022

IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

GlobeNewswire March 28, 2022

IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 17, 2022

IN8bio to present at March Investor and Scientific Conferences

GlobeNewswire March 4, 2022

IN8bio to present at Bio CEO & Investor Conference and Next Generation CAR-TCR Summit

GlobeNewswire February 10, 2022

IN8bio to Present at Upcoming January Investor Conferences

GlobeNewswire January 10, 2022

IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme

GlobeNewswire January 6, 2022

IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

GlobeNewswire December 16, 2021